Trial Profile

Prospective intervention study of novel SGLT-2 inhibitor ipragliflozin in patients with type 2 diabetes

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 29 Dec 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ipragliflozin (Primary)
Indications Type 2 diabetes mellitus
Focus Therapeutic Use

Most Recent Events

25 Dec 2017 Status changed from active, no longer recruiting to completed.
12 Apr 2016 Status changed from recruiting to active, no longer recruiting.
25 Aug 2015 Status changed from not yet recruiting to recruiting, as reported by University Hospital Medical Information Network - Japan

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com